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reported: CSA vs Age, CTDIvol vs CSA, DLP vs CSA, CTDIvol by 
Patient, DLP by Patient. 
 
Results: The mean scan length, DLP, CTDIvol and Effective 
Dose by Protocol were found for each protocol. The most 
significant result was that the DLP values from the Head & 
Neck protocol were tightly clustered but higher than one 
would normally expect. The mean DLP was a factor of 4 
greater than the head and neck reference level reported in 
the previous UK national (diagnostic CT) dose audit. 
 
 
 
Conclusion: The results from this CT dose audit can be used 
as local Radiotherapy Imaging Reference Levels (RIRL). They 
will be able to guide protocol optimisation, allow comparison 
with other similarly equipped radiotherapy departments and 
participation in regional and national audits. The higher than 
expected DLP values for the Head & Neck protocol 
highlighted here has prompted a reassessment of the 
scanning parameters and may lead to protocol optimisation. 
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Purpose or Objective: Radiation safety for softer flattening 
filter free (FFF) treatment beams when operating at their 
very high dose rates should be considered over that of their 
flattening filter (FF) counterparts. Existing shielding is usually 
adequate when replacing treatment units utilizing beams of 
FF only with FFF-beams of the same nominal energy(1). 
However, depending upon the existing shielding composition 
and thickness, workload, and occupancy factors, the 
instantaneous dose rate (IDR) may present a radiation safety 
concern. 
 
Material and Methods: A generalized analysis is presented 
with regards to replacing a unit which has only FF-beams to 
one with FFF-beams in a pre-existing bunker. Extra focus is 
placed on the situation that radiation levels around the 
treatment bunker are already at the radiation safety 
threshold for the unit being replaced. This threshold 
condition varies with the radiation safety regulations of the 
land. For example, the Canadian Nuclear Safety Commission 
(CNSC) imposes a condition that the IDR be less than 25 μSv/h 
to deem an area uncontrolled(3). The United States National 
Regulatory Council (US NRC) regulates the time averaged 
dose rate (TADR) to be less than 20μSv in any one hour(2).  
 
Results: It is demonstrated that in switching to FFF-beam 
treatment units that protection using existing shielding is 
maintained for annual and weekly equivalent dose protection 
levels. However, it is possible for the CNSC IDR condition to 
be exceeded at the highest dose rates for FFF-beams. Thus 
shielding modification should be considered along with the 
ALARA principle(4). An analysis of the latter point is 
presented in general and by example from such a treatment 
unit replacement at the London Regional Cancer Program. 
The US NRC regulation is not as stringent as the Canadian 
condition and is almost impossible to exceed if the conditions 
before replacement were met. The analysis of this result is 
presented in general. 
 
Conclusion: Care must be taken when considering 
thereplacement of radiation treatment units with FF-beams 
to those with FFF-beamswith respect to radiation protection. 
Radiation protection from the existingshielding is maintained 
for annual and weekly protection levels. However, IDR may 
present a radiation safety concern dependingupon radiation 
safety regulations in the country of its location. In 
Canada,the possibility exists that this threshold can be 
exceeded. The US NRCcondition is almost impossible to 
exceed. 
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Purpose or Objective: In image-guided radiotherapy, 
imaging dose varies greatly with the imaging technique. We 
here present imaging doses from planar and cone-beam CT 
(CBCT) imaging for three different on-board imaging 
techniques: the treatment beam line (TBL, 6 MV), a 
dedicated imaging beam line termed kView of nominally 1 MV 
(IBL), and a kilovoltage system (kVision) at 70-121 kV photon 
energy. We consider two collectives of patients with common 
IGRT indications: head-and-neck and prostate cancer. 
 
Material and Methods: In this study, we retrospectively 
analyzed imaging dose of 54 patients with head-and-neck 
cancer and 53 with prostate cancer treated in 2013. For all 
patients, the number of verification images (CBCT and axes) 
was determined, separately for the three systems (more than 
1000 images). The dose for each verification image was 
calculated in the Philips Pinnacle treatment planning system 
on a 2 mm grid using the collapsed cone algorithm. We 
evaluated the dose maximum and dose to the organs at risk, 
considering the total imaging dose, and for the techniques (6 
MV, IBL, kV, planar vs. CBCT) separately. 
 
Results: The calculated imaging doses are given in Table 1. 
Both the TBL and IBL modality entail considerable imaging 
dose, even for orthogonal axes. The maximum dose value for 
each image, averaged over all prostate patients, was 14.8 
cGy (6 MV CBCT)/ 2.8 cGy (19 %; 6 MV axes)/ 10.5 cGy (71 %; 
IBL CBCT)/ 2.1 cGy (14 %; IBL axes)/ 3.8 cGy (26 %; kV CBCT), 
where percentage values refer to the 6 MV CBCT dose. As can 
be seen, kV CBCT still amounts to 26 % the imaging dose from 
MV CBCT, and about twice the dose from IBL axes. Averaged 
over the collective of head-and-neck cancer patients, the 
maximum imaging dose was 8.4 cGy (6 MV CBCT)/ 2.6 cGy (31 
%; 6 MV axes)/ 6.2 cGy (74 %; IBL CBCT)/ 2.3 cGy (27 %; IBL 
axes)/ 0.9 cGy (11 %; kV CBCT). Here, the dose reduction 
from axial images was not as pronounced because less 
monitor units were used for MV CBCT. kV CBCT reduced the 
dose further because of low mAs values chosen by the auto-
exposure mechanism. 
 
